In-vitro Diagnostics (IVD) Reagents Market - Global Outlook & Forecast 2025-2030
THE GLOBAL IVD REAGENTS MARKET SIZE IS EXPECTED TO REACH USD 96.17 BILLION BY 2030 FROM USD 77.56 BILLION IN 2024, GROWING AT A CAGR OF 3.65% DURING THE FORECAST PERIOD.
THE GLOBAL IVD REAGENTS MARKET SIZE IS EXPECTED TO REACH USD 96.17 BILLION BY 2030 FROM USD 77.56 BILLION IN 2024, GROWING AT A CAGR OF 3.65% DURING THE FORECAST PERIOD.
The IVD Reagents Market Size, Share, & Trends Analysis Report By
- Reagent Type: Immunochemical Reagents, Biochemical Reagents, and Chemical Reagents
- Technology: Immunoassay & Clinical Chemistry, Molecular Diagnostics, Hematology, Microbiology & Cytology, and Others
- Application: Infectious Diseases, Diabetes, Cardiology, Oncology, Autoimmune Diseases, and Others
- End-users: Standard Reference Labs, Hospital-affiliated Labs, Clinics, and Others
- Geography: North America, Europe, APAC, Latin America, and Middle East & Africa
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030.
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
GLOBAL IVD REAGENTS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2030) | USD 96.17 Billion |
| Market Size (2024) | USD 77.56 Billion |
| CAGR (2024-2030) | 3.65% |
| HISTORIC YEAR | 2021-2023 |
| BASE YEAR | 2024 |
| FORECAST YEAR | 2025-2030 |
| SEGMENTS BY | Reagent Type, Technology, Application, End-users, and Geography |
| GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY PLAYERS | Abbott, Danaher, F. Hoffmann La-Roche, Siemens Healthineers, and Thermo Fisher Scientific |
IVD REAGENTS MARKET SIZE & OUTLOOK
The global IVD reagents market was valued at USD 77.56 billion in 2024 and is expected to reach USD 96.17 billion by 2030. The market is experiencing dynamic growth, driven by rapid advancements in diagnostic technologies, the increasing burden of chronic and infectious diseases, and the shift toward precision medicine. As healthcare systems prioritize early disease detection, efficient treatment monitoring, and decentralized testing, the demand for high-quality IVD reagents continues to rise.
The IVD reagents market is poised for substantial growth, fueled by technological breakthroughs and increasing global healthcare needs. With a CAGR projected of 3.65% over the forecasting period, the market is expanding across various diagnostic segments, including molecular diagnostics, immunoassays, hematology, and microbiology. Moreover, the global IVD reagents market is highly competitive, with key players investing in research and development, strategic collaborations, and mergers to strengthen their market presence. Companies are focusing on AI-driven automation, multiplex testing, and lab-on-a-chip technologies to revolutionize diagnostics. Market leaders are prioritizing compliance with stringent regulations such as FDA approvals and EU IVDR certification to ensure reliability and global market access. Mergers between diagnostic firms and biotechnology companies are fostering innovation and expanding product portfolios.
The global IVD reagents market presents unparalleled growth opportunities, with advancements in precision diagnostics, molecular testing, and digital healthcare driving demand. Early adopters and strategic investors stand to benefit from rapid innovation, expanding market reach, and increasing consumer reliance on diagnostic testing. By staying ahead of industry trends, leveraging cutting-edge technologies, and navigating regulatory landscapes effectively, businesses can secure a competitive edge in this high-growth sector.
MARKET TRENDS & DRIVERS
Rising Significance of Biomarker Discovery & Companion Diagnostics
The expanding importance of biomarker discovery and companion diagnostics is reshaping the IVD reagents market. As personalized medicine continues to advance, the demand for high-quality reagents that enable precise biomarker detection and CDx assays is on the rise. Market players who invest in innovative reagent development, form strategic partnerships, and expand into emerging applications will be well-positioned to capitalize on this growing sector. In a time where precision diagnostics is becoming the gold standard, IVD reagent manufacturers have a critical role to play in shaping the future of healthcare.
Rise of Point-of-Care (POC) Testing
Point-of-care testing is transforming the diagnostic landscape, leading to a surge in demand for high-quality IVD reagents. With the emergence of decentralized, rapid, and personalized healthcare diagnostics, reagent manufacturers have an opportunity to expand their market presence through innovation. The growing demand for POC testing is being met by companies, that are utilizing advanced molecular reagents, multiplex testing solutions, and digital-friendly diagnostic receptacles.
Increasing Demand for Customized Diagnostic Tests & Personalized Medicine
The increasing demand for customized diagnostic tests and personalized medicine is shaping the future of the global IVD reagents market. With advancements in molecular diagnostics, AI-driven testing, and regulatory support for precision medicine, the market is poised for strong growth. Companies that invest in innovation, strategic collaborations, and emerging market expansion will be well-positioned to capitalize on the growing demand for customized IVD solutions.
Expansion of AI and Automation in Diagnostics
As laboratories and healthcare providers increasingly adopt AI-driven systems, the demand for high-quality, automation-friendly IVD reagents will continue to rise. While ongoing technological advancements and strategic collaborations will drive innovation, positioning AI-powered diagnostics as a cornerstone of the future healthcare landscape. Manufacturers that embrace AI-compatible reagent development will be well-positioned to capitalize on this growing market trend.
Growing Prevalence of Chronic & Infectious Diseases
The increasing prevalence of chronic and infectious diseases is a key driver of the global IVD reagents market. The demand for accurate, fast, and cost-effective diagnostic solutions continues to grow, supported by technological advancements and rising healthcare investments. Specifically in emerging economies and personalized medicine applications. Moving forward, innovation in reagent development will play a crucial role in shaping the future of diagnostic testing.
Growing Awareness & Early Disease Detection
The global IVD reagents market is experiencing robust growth due to rising awareness about early disease detection and preventive healthcare. The increasing prevalence of chronic and infectious diseases, coupled with advancements in diagnostic technologies, is driving demand for high-quality IVD reagents. Government initiatives, home-based testing trends, and rapid innovation in molecular diagnostics are further fueling industry expansion.
Innovations in Reagent Formulations
Advances in molecular reagents, lyophilized formulations, automation-friendly solutions, nanotechnology, and eco-friendly alternatives are enhancing diagnostic accuracy, efficiency, and accessibility. Continued R&D and strategic collaborations will accelerate innovation, shaping the future of the IVD industry. As the demand for high-performance diagnostics continues to rise, the market for advanced IVD reagents is poised for substantial growth in the coming years.
Expanding Healthcare Infrastructure & Investments in R&D
The global IVD reagents market is witnessing robust growth, fueled by expanding healthcare infrastructure and increased investments in R&D. As healthcare systems worldwide focus on early disease detection and precision diagnostics, the demand for innovative and high-quality reagents will continue to rise. Ongoing technological advancements and strategic collaborations will drive further industry expansion, ultimately improving healthcare outcomes on a global scale.
SEGMENTATION INSIGHTS
INSIGHTS BY REAGENT TYPE
The global IVD reagents market is segmented by reagent type into immunochemical reagents, biochemical reagents, and chemical reagents, each playing a crucial role in diagnostic testing. Immunochemical reagents are widely used in immunoassays such as ELISA and chemiluminescence assays to detect antigens, antibodies, hormones, and infectious agents, making them essential for disease diagnosis and monitoring. Biochemical reagents are used in enzymatic and metabolic assays to measure biomarkers like glucose, cholesterol, and liver enzymes, playing a key role in clinical chemistry and metabolic disorder detection. Chemical reagents are primarily used in general laboratory tests and hematology assays, facilitating reactions that help analyze blood components, coagulation factors, and electrolyte levels. With increasing demand for early disease detection, personalized medicine, and point-of-care diagnostics, all three reagent types are driving industry growth globally, supported by technological advancements and expanding healthcare infrastructure.
INSIGHTS BY TECHNOLOGY
The global IVD reagents market is segmented by technology into immunoassay & clinical chemistry, molecular diagnostics, hematology, microbiology & cytology, and others, each playing a crucial role in disease detection and monitoring. Immunoassay & clinical chemistry dominate the industry due to its widespread use in hormone testing, infectious disease detection, and chronic disease monitoring. Molecular diagnostics is rapidly growing, driven by advancements in PCR, next-generation sequencing (NGS), and companion diagnostics, particularly in oncology and genetic testing. Hematology reagents are essential for blood analysis, including complete blood counts (CBC) and coagulation tests, which are critical for diagnosing blood disorders and managing treatments. Microbiology & cytology reagents aid in identifying bacterial, viral, and fungal infections through culture-based and rapid antigen tests, while cytology reagents are used in cancer screening, such as Pap smears.
INSIGHTS BY APPLICATION
The global IVD reagents market is segmented by application into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, and others. Infectious diseases dominate the market due to the high prevalence of viral and bacterial infections, including COVID-19, HIV, and tuberculosis, driving demand for rapid and molecular diagnostic reagents. Diabetes testing is a significant segment, fueled by the increasing global burden of diabetes and the need for continuous glucose monitoring. Cardiology diagnostics utilize IVD reagents for detecting biomarkers like troponins and cholesterol levels, aiding in the early diagnosis and management of cardiovascular diseases. Oncology applications are growing rapidly with advancements in molecular diagnostics and biomarker-based testing for personalized cancer treatment. Autoimmune disease diagnostics, including rheumatoid arthritis and lupus testing, rely on immunoassay-based reagents for accurate disease detection. The other categories include neurology, nephrology, and genetic testing applications, further contributing to the expansion of the global IVD reagents market.
INSIGHTS BY END-USER
The global IVD reagents market is segmented by end-users, including standard reference labs, hospital-affiliated labs, clinics, and others, each playing a crucial role in diagnostic testing. Standard reference labs dominate the industry due to their high testing volumes, advanced infrastructure, and capability to conduct specialized and high-complexity diagnostic tests. Hospital-affiliated labs hold a significant share of the IVD reagents market as they provide immediate and integrated diagnostic services for inpatients and emergency cases, ensuring faster treatment decisions. Clinics contribute to industry growth by offering point-of-care and routine diagnostic testing, particularly for chronic disease management and infectious disease screening. The other categories include ambulatory care centers, blood banks, industrial laboratories, physician offices, mobile diagnostic centers, and research & academic institutes, which are expanding due to increasing demand for decentralized and personalized diagnostic solutions.
IVD REAGENTS MARKET GEOGRAPHICAL ANALYSIS
North America holds the largest share of the global IVD reagents market in 2024, accounting for over 38%. The North American IVD reagents market is one of the most advanced and rapidly growing segments in the global healthcare industry. Driven by technological advancements, rising chronic disease prevalence, and increasing demand for rapid and accurate diagnostics, the region holds a significant share of the global market. The U.S. and Canada, with their well-established healthcare infrastructure and strong regulatory frameworks, are key contributors to industry growth. Moreover, the rising prevalence of cancer, diabetes, cardiovascular diseases, and infectious diseases is fueling demand for advanced diagnostic reagents in the region. An aging population requires frequent diagnostic testing for chronic disease management and early disease detection.
Europe is the second-largest market in the global IVD reagents market, driven by strong diagnostic research, widespread adoption of IVD regulations (IVDR), and increased funding for healthcare innovation. Germany, France, Russia, and Italy lead in industry share due to robust laboratory infrastructure and government support for early disease detection. Furthermore, APAC is the fastest-growing market in the global IVD reagents market during the forecast period, driven by rising healthcare investments, increasing prevalence of chronic diseases, and a growing middle-class population. Countries like China, Japan, and India are major contributors due to expanding healthcare access and government initiatives for disease screening. Latin America and the Middle East & Africa are emerging IVD reagents markets with strong potential, driven by rising healthcare investments and the need for improved diagnostics.
VENDOR LANDSCAPE
The global IVD reagents market is highly competitive and dynamic within the broader medical diagnostics industry. As healthcare systems increasingly rely on early disease detection, personalized medicine, and point-of-care testing, the demand for reliable and innovative IVD reagents has surged. This demand has led to intensified competition among global players, characterized by innovation, strategic alliances, aggressive market expansion, and pricing pressure. Furthermore, as consumer demand for convenience grows, companies in the IVD reagents market will compete to develop user-friendly, self-testing kits that offer lab-quality results at home. Companies will increasingly focus on targeted diagnostics for specific populations, diseases, or genetic profiles, creating competition in highly specialized niches. Emerging technologies like biosensors, nanotechnology, and lab-on-a-chip platforms will be central to next-gen reagent development and will define future competitive advantage.
The global IVD reagents market is fiercely competitive, shaped by constant innovation, evolving healthcare needs, and emerging technologies. Major players are leveraging product development, global expansion, strategic collaborations, and digital integration to strengthen their market position. However, this rapidly evolving landscape also presents challenges such as regulatory compliance, cost pressures, and technological disruptions. Looking ahead, companies that prioritize agility, innovation, and localized strategies will be best positioned to lead and thrive in the future of diagnostics.
Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are among the key players shaping the global in vitro diagnostics (IVD) reagents market. Abbott stands out as a global leader in this space, offering a comprehensive portfolio of reagent-based solutions across its core laboratory, molecular, point-of-care, and rapid diagnostics segments. Leveraging advanced platforms such as ARCHITECT, Alinity, and ID NOW, Abbott delivers high-throughput and rapid diagnostic capabilities in areas including immunoassays, clinical chemistry, infectious disease detection, and cardiac biomarkers. Its extensive global footprint, strong R&D investments, and established presence in both mature and emerging markets firmly position Abbott as a dominant force in the IVD reagents market.
SNAPSHOT
The global IVD reagents market size is expected to grow at a CAGR of approximately 3.65% from 2024 to 2030.
The following factors are likely to contribute to the growth of the IVD reagents market during the forecast period:
- Growing Prevalence of Chronic & Infectious Diseases
- Growing Awareness & Early Disease Detection
- Innovations in the Reagent Formulations
- Expanding Healthcare Infrastructure & Investments in R&D
Base Year: 2024
Forecast Year: 2025-2030
The report considers the present scenario of the global IVD reagents market and its market dynamics for 2025−2030. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
- Abbott
- Business Overview
- Product Offerings
- Key Strategies
- Key Strengths
- Key Opportunities
- Danaher
- F. Hoffmann La-Roche
- Siemens Healthineers
- Thermo Fisher Scientific
Other Prominent Vendors
- Atomo Diagnostics
- Business Overview
- Product Offerings
- Accelerate Diagnostics
- Agilent Technologies
- altona Diagnostics
- Amoy Diagnostics
- ARKRAY
- AccuBioTech
- The Binding Site Group
- BD
- Bio-Rad Laboratories
- BIOMÉRIEUX
- bioLytical Laboratories
- Biocartis
- Biocept
- Biomerica
- Bioway Biological Technology
- Boule Diagnostics
- Cupid
- Chembio Diagnostics
- CPC Diagnostics
- CPM Scientifica
- DIALAB GmbH
- DiaSorin S.p.A.
- Diagon
- EDAN Instruments
- Illumina
- Merck KGaA
- MP Biomedicals
- OraSure Technologies
- QIAGEN
- QuidelOrtho
Segmentation by Reagent Type
- Immunochemical Reagents
- Biochemical Reagents
- Chemical Reagents
Segmentation by Technology
- Immunoassay & Clinical Chemistry
- Molecular Diagnostics
- Hematology
- Microbiology & Cytology
- Others
Segmentation by Application
- Infectious Diseases
- Diabetes
- Cardiology
- Oncology
- Autoimmune Diseases
- Others
Segmentation by End-users
- Standard Reference Labs
- Hospital-affiliated Labs
- Clinics
- Others
Segmentation by Geography
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Russia
- Spain
- Italy
- The U.K.
- Netherlands
- APAC
- China
- Japan
- India
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- Turkey
- Suadi Arabia
- South Africa
- UAE
IVD REAGENTS MARKET FAQs
How big is the global IVD reagents market?
What is the growth rate of the global IVD reagents market?
Which region dominates the global IVD reagents market share?
What are the significant trends in the IVD reagents market?
Who are the key players in the global IVD reagents market?
EXHIBIT 1 MARKET SIZE CALCULATION APPROACH (2024)
EXHIBIT 2 GLOBAL IVD REAGENTS MARKET BY GEOGRAPHY: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 3 GLOBAL IVD REAGENTS MARKET BY REAGENT TYPE: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 4 GLOBAL IVD REAGENTS MARKET BY TECHNOLOGY: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 5 GLOBAL IVD REAGENTS MARKET BY APPLICATION: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 6 GLOBAL IVD REAGENTS MARKET BY END-USER: MARKET SHARE 2024 & 2030 (%)
EXHIBIT 7 IMPACT OF RISING SIGNIFICANCE OF BIOMARKER DISCOVERY & COMPANION DIAGNOSTICS
EXHIBIT 8 IMPACT OF RISE OF POINT-OF-CARE (POC) TESTING
EXHIBIT 9 IMPACT OF INCREASING DEMAND FOR CUSTOMIZED DIAGNOSTIC TESTS & PERSONALIZED MEDICINE
EXHIBIT 10 IMPACT OF EXPANSION OF AI AND AUTOMATION IN DIAGNOSTICS
EXHIBIT 11 IMPACT OF GROWING PREVALENCE OF CHRONIC & INFECTIOUS DISEASES
EXHIBIT 12 IMPACT OF GROWING AWARENESS & EARLY DISEASE DETECTION
EXHIBIT 13 IMPACT OF INNOVATIONS ON REAGENT FORMULATIONS
EXHIBIT 14 IMPACT OF EXPANDING HEALTHCARE INFRASTRUCTURE & INVESTMENTS IN R&D
EXHIBIT 15 IMPACT OF HIGH COST OF ADVANCED DIAGNOSTIC TESTS
EXHIBIT 16 IMPACT OF SUPPLY CHAIN DISRUPTIONS & RAW MATERIAL SHORTAGES
EXHIBIT 17 IMPACT OF STRINGENT REGULATORY REQUIREMENTS
EXHIBIT 18 GLOBAL IVD REAGENTS MARKET 2021–2030 ($ BILLION)
EXHIBIT 19 FIVE FORCES ANALYSIS (2024)
EXHIBIT 20 INCREMENTAL GROWTH BY REAGENT TYPE (2024 & 2030)
EXHIBIT 21 GLOBAL IVD REAGENTS MARKET BY REAGENT TYPE 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 22 GLOBAL IVD REAGENTS MARKET BY REAGENT TYPE 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 23 GLOBAL IMMUNOCHEMICAL IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 24 GLOBAL IMMUNOCHEMICAL IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 25 GLOBAL BIOCHEMICAL IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 26 GLOBAL BIOCHEMICAL IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 27 GLOBAL CHEMICAL IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 28 GLOBAL CHEMICAL IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 29 INCREMENTAL GROWTH BY TECHNOLOGY (2024 & 2030)
EXHIBIT 30 GLOBAL IVD REAGENTS MARKET BY TECHNOLOGY 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 31 GLOBAL IVD REAGENTS MARKET BY TECHNOLOGY 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 32 GLOBAL IMMUNOASSAY & CLINICAL CHEMISTRY IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 33 GLOBAL IMMUNOASSAY & CLINICAL CHEMISTRY IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 34 GLOBAL MOLECULAR DIAGNOSTICS IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 35 GLOBAL MOLECULAR DIAGNOSTICS IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 36 GLOBAL HEMATOLOGY IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL HEMATOLOGY IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 38 GLOBAL MICROBIOLOGY & CYTOLOGY IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL MICROBIOLOGY & CYTOLOGY IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 40 GLOBAL OTHER IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 GLOBAL OTHER IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 42 INCREMENTAL GROWTH BY APPLICATION (2024 & 2030)
EXHIBIT 43 GLOBAL IVD REAGENTS MARKET BY APPLICATION 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 44 GLOBAL IVD REAGENTS MARKET BY APPLICATION 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 45 GLOBAL INFECTIOUS DISEASES IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 46 GLOBAL INFECTIOUS DISEASES IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 47 GLOBAL DIABETES IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL DIABETES IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 49 GLOBAL CARDIOLOGY IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 GLOBAL CARDIOLOGY IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 51 GLOBAL ONCOLOGY IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL ONCOLOGY IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 53 GLOBAL AUTOIMMUNE DISEASES IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 54 GLOBAL AUTOIMMUNE DISEASES IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 55 GLOBAL OTHER IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL OTHER IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY END-USER (2024 & 2030)
EXHIBIT 58 GLOBAL IVD REAGENTS MARKET BY END-USER 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 59 GLOBAL IVD REAGENTS MARKET BY END-USER 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 60 GLOBAL STANDARD REFERENCE LABS IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 61 GLOBAL STANDARD REFERENCE LABS IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 62 GLOBAL HOSPITAL-AFFILIATED LABS IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 63 GLOBAL HOSPITAL-AFFILIATED LABS IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 64 GLOBAL CLINICS IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 65 GLOBAL CLINICS IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 66 GLOBAL OTHER IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 67 GLOBAL OTHER IVD REAGENTS MARKET 2021-2030 ($ BILLION)
EXHIBIT 68 INCREMENTAL GROWTH BY GEOGRAPHY (2024 & 2030)
EXHIBIT 69 GLOBAL IVD REAGENTS MARKET BY GEOGRAPHY 2024-2030: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 70 GLOBAL IVD REAGENTS MARKET BY GEOGRAPHY 2024-2030: ABSOLUTE GROWTH (%)
EXHIBIT 71 NORTH AMERICA IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 IVD REAGENTS MARKET IN NORTH AMERICA 2021–2030 ($ BILLION)
EXHIBIT 73 INCREMENTAL GROWTH IN NORTH AMERICA (2024 & 2030)
EXHIBIT 74 US IVD REAGENTS MARKET 2021–2030 ($ BILLION)
EXHIBIT 75 IVD REAGENTS MARKET IN CANADA 2021–2030 ($ BILLION)
EXHIBIT 76 EUROPE IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 77 IVD REAGENTS MARKET IN EUROPE 2021–2030 ($ BILLION)
EXHIBIT 78 INCREMENTAL GROWTH IN EUROPE (2024 & 2030)
EXHIBIT 79 IVD REAGENTS MARKET IN GERMANY 2021–2030 ($ BILLION)
EXHIBIT 80 IVD REAGENTS MARKET IN FRANCE 2021–2030 ($ BILLION)
EXHIBIT 81 IVD REAGENTS MARKET IN RUSSIA 2021–2030 ($ BILLION)
EXHIBIT 82 IVD REAGENTS MARKET IN SPAIN 2021–2030 ($ BILLION)
EXHIBIT 83 IVD REAGENTS MARKET IN ITALY 2021–2030 ($ BILLION)
EXHIBIT 84 UK IVD REAGENTS MARKET 2021–2030 ($ BILLION)
EXHIBIT 85 IVD REAGENTS MARKET IN NETHERLANDS 2021–2030 ($ BILLION)
EXHIBIT 86 APAC IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 87 APAC IVD REAGENTS MARKET 2021–2030 ($ BILLION)
EXHIBIT 88 INCREMENTAL GROWTH IN APAC (2024 & 2030)
EXHIBIT 89 IVD REAGENTS MARKET IN CHINA 2021–2030 ($ BILLION)
EXHIBIT 90 IVD REAGENTS MARKET IN JAPAN 2021–2030 ($ BILLION)
EXHIBIT 91 IVD REAGENTS MARKET IN INDIA 2021–2030 ($ BILLION)
EXHIBIT 92 IVD REAGENTS MARKET IN SOUTH KOREA 2021–2030 ($ BILLION)
EXHIBIT 93 IVD REAGENTS MARKET IN AUSTRALIA 2021–2030 ($ BILLION)
EXHIBIT 94 LATIN AMERICA IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 95 IVD REAGENTS MARKET IN LATIN AMERICA 2021–2030 ($ BILLION)
EXHIBIT 96 INCREMENTAL GROWTH IN LATIN AMERICA (2024 & 2030)
EXHIBIT 97 IVD REAGENTS MARKET IN BRAZIL 2021–2030 ($ BILLION)
EXHIBIT 98 IVD REAGENTS MARKET IN MEXICO 2021–2030 ($ BILLION)
EXHIBIT 99 IVD REAGENTS MARKET IN ARGENTINA 2021–2030 ($ BILLION)
EXHIBIT 100 IVD REAGENTS MARKET IN COLOMBIA 2021–2030 ($ BILLION)
EXHIBIT 101 MIDDLE EAST & AFRICA IVD REAGENTS MARKET 2024-2030: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 102 IVD REAGENTS MARKET IN MIDDLE EAST & AFRICA 2021–2030 ($ BILLION)
EXHIBIT 103 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA (2024 & 2030)
EXHIBIT 104 IVD REAGENTS MARKET IN TURKEY 2021–2030 ($ BILLION)
EXHIBIT 105 IVD REAGENTS MARKET IN SAUDI ARABIA 2021–2030 ($ BILLION)
EXHIBIT 106 IVD REAGENTS MARKET IN SOUTH AFRICA 2021–2030 ($ BILLION)
EXHIBIT 107 UAE IVD REAGENTS MARKET 2021–2030 ($ BILLION)
EXHIBIT 108 VENDORS OFFERING IVD REAGENTS: MARKET DOMINANCE ANALYSIS
EXHIBIT 109 VENDORS OFFERING COMMERCIAL IVD REAGENTS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 110 KEY CAVEATS
LIST OF TABLES
TABLE 1 GLOBAL IMMUNOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 2 GLOBAL IMMUNOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 3 GLOBAL BIOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 4 GLOBAL BIOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 5 GLOBAL CHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 6 GLOBAL CHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 7 GLOBAL IMMUNOASSAY & CLINICAL CHEMISTRY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 8 GLOBAL IMMUNOASSAY & CLINICAL CHEMISTRY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 9 GLOBAL MOLECULAR DIAGNOSTICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 10 GLOBAL MOLECULAR DIAGNOSTICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 11 GLOBAL HEMATOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 12 GLOBAL HEMATOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 13 GLOBAL MICROBIOLOGY & CYTOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 14 GLOBAL MICROBIOLOGY & CYTOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 15 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 16 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 17 GLOBAL INFECTIOUS DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 18 GLOBAL INFECTIOUS DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 19 GLOBAL DIABETES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 20 GLOBAL DIABETES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 21 GLOBAL CARDIOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 22 GLOBAL CARDIOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 23 GLOBAL ONCOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 24 GLOBAL ONCOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 25 GLOBAL AUTOIMMUNE DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 26 GLOBAL AUTOIMMUNE DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 27 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 28 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 29 GLOBAL STANDARD REFERENCE LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 30 GLOBAL STANDARD REFERENCE LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 31 GLOBAL HOSPITAL-AFFILIATED LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 32 GLOBAL HOSPITAL-AFFILIATED LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 33 GLOBAL CLINICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 34 GLOBAL CLINICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 35 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 36 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 37 NORTH AMERICA IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 ($ BILLION)
TABLE 38 NORTH AMERICA IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 (%)
TABLE 39 NORTH AMERICA IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 40 NORTH AMERICA IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 41 NORTH AMERICA IVD REAGENTS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 42 NORTH AMERICA IVD REAGENTS MARKET BY APPLICATION 2024−2030 (%)
TABLE 43 NORTH AMERICA IVD REAGENTS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 44 NORTH AMERICA IVD REAGENTS MARKET BY END-USER 2024−2030 (%)
TABLE 45 EUROPE IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 ($ BILLION)
TABLE 46 EUROPE IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 (%)
TABLE 47 EUROPE IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 48 EUROPE IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 49 EUROPE IVD REAGENTS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 50 EUROPE IVD REAGENTS MARKET BY APPLICATION 2024−2030 (%)
TABLE 51 EUROPE IVD REAGENTS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 52 EUROPE IVD REAGENTS MARKET BY END-USER 2024−2030 (%)
TABLE 53 APAC IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 ($ BILLION)
TABLE 54 APAC IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 (%)
TABLE 55 APAC IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 56 APAC IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 57 APAC IVD REAGENTS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 58 APAC IVD REAGENTS MARKET BY APPLICATION 2024−2030 (%)
TABLE 59 APAC IVD REAGENTS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 60 APAC IVD REAGENTS MARKET BY END-USER 2024−2030 (%)
TABLE 61 LATIN AMERICA IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 ($ BILLION)
TABLE 62 LATIN AMERICA IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 (%)
TABLE 63 LATIN AMERICA IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 64 LATIN AMERICA IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 65 LATIN AMERICA IVD REAGENTS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 66 LATIN AMERICA IVD REAGENTS MARKET BY APPLICATION 2024−2030 (%)
TABLE 67 LATIN AMERICA IVD REAGENTS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 68 LATIN AMERICA IVD REAGENTS MARKET BY END-USER 2024−2030 (%)
TABLE 69 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 ($ BILLION)
TABLE 70 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY REAGENT TYPE 2024−2030 (%)
TABLE 71 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 ($ BILLION)
TABLE 72 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY TECHNOLOGY 2024−2030 (%)
TABLE 73 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY APPLICATION 2024−2030 ($ BILLION)
TABLE 74 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY APPLICATION 2024−2030 (%)
TABLE 75 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY END-USER 2024−2030 ($ BILLION)
TABLE 76 MIDDLE EAST & AFRICA IVD REAGENTS MARKET BY END-USER 2024−2030 (%)
TABLE 77 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 78 DANAHER: MAJOR PRODUCT OFFERINGS
TABLE 79 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 80 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS
TABLE 81 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 82 ATOMO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 83 ACCELERATE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 84 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 85 ALTONA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 86 AMOY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 87 ARKRAY: MAJOR PRODUCT OFFERINGS
TABLE 88 ACCUBIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 89 BD: MAJOR PRODUCT OFFERINGS
TABLE 90 BIORAD LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 91 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS
TABLE 92 BIOLYTICAL LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 93 BIOCARTIS: MAJOR PRODUCT OFFERINGS
TABLE 94 BIOCEPT: MAJOR PRODUCT OFFERINGS
TABLE 95 BIOMERICA: MAJOR PRODUCT OFFERINGS
TABLE 96 BIOWAY BIOLOGICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 97 BOULE: MAJOR PRODUCT OFFERINGS
TABLE 98 CUPID: MAJOR PRODUCT OFFERINGS
TABLE 99 CHEMBIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 100 CPC DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 101 CPM SCIENTIFICA: MAJOR PRODUCT OFFERINGS
TABLE 102 DIALAB GMBH: MAJOR PRODUCT OFFERINGS
TABLE 103 DIASORIN S.P.A.: MAJOR PRODUCT OFFERINGS
TABLE 104 DIAGON: MAJOR PRODUCT OFFERINGS
TABLE 105 EDAN INSTRUMENTS: MAJOR PRODUCT OFFERINGS
TABLE 106 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 107 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 108 MP BIOMEDICALS: MAJOR PRODUCT OFFERINGS
TABLE 109 ORASURE TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 110 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 111 QUIDELORTHO: MAJOR PRODUCT OFFERINGS
TABLE 112 GLOBAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 113 GLOBAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 114 GLOBAL IMMUNOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 115 GLOBAL IMMUNOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 116 GLOBAL BIOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 117 GLOBAL BIOCHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 118 GLOBAL CHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 119 GLOBAL CHEMICAL IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 120 GLOBAL IMMUNOASSAY & CLINICAL CHEMISTRY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 121 GLOBAL IMMUNOASSAY & CLINICAL CHEMISTRY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 122 GLOBAL MOLECULAR DIAGNOSTICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 123 GLOBAL MOLECULAR DIAGNOSTICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 124 GLOBAL HEMATOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 125 GLOBAL HEMATOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 126 GLOBAL MICROBIOLOGY & CYTOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 127 GLOBAL MICROBIOLOGY & CYTOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 128 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 129 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 130 GLOBAL INFECTIOUS DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 131 GLOBAL INFECTIOUS DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 132 GLOBAL DIABETES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 133 GLOBAL DIABETES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 134 GLOBAL CARDIOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 135 GLOBAL CARDIOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 136 GLOBAL ONCOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 137 GLOBAL ONCOLOGY IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 138 GLOBAL AUTOIMMUNE DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 139 GLOBAL AUTOIMMUNE DISEASES IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 140 GLOBAL OTHER APPLICATION IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 141 GLOBAL OTHER APPLICATION IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 142 GLOBAL STANDARD REFERENCE LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 143 GLOBAL STANDARD REFERENCE LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 144 GLOBAL HOSPITAL-AFFILIATED LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 145 GLOBAL HOSPITAL-AFFILIATED LABS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 146 GLOBAL CLINICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 147 GLOBAL CLINICS IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 148 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 ($ BILLION)
TABLE 149 GLOBAL OTHER IVD REAGENTS MARKET BY GEOGRAPHY 2024−2030 (%)
TABLE 150 CURRENCY CONVERSION (2018−2024)
- 1. SCOPE & COVERAGE
- 1.1. MARKET DEFINITION
- 1.1.1. INCLUSIONS
- 1.1.2. EXCLUSIONS
- 1.1.3. MARKET ESTIMATION CAVEATS
- 1.1.4. MARKET SEGMENTATION COVERAGE & DEFINITIONS
- 1.1.5. BY REAGENT TYPE
- 1.1.6. BY TECHNOLOGY
- 1.1.7. BY APPLICATION
- 1.1.8. BY END-USER
- 1.1.9. REGIONS & COUNTRIES COVERED:
- 1.2. MARKET DERIVATION
- 1.2.1. BASE YEAR
- 2. PREMIUM INSIGHTS
- 2.1. OPPORTUNITY POCKETS
- 2.2. OVERVIEW
- 3. MARKET AT A GLANCE
- 4. INTRODUCTION
- 4.1. OVERVIEW
- 5. MARKET OPPORTUNITIES & TRENDS
- 5.1. RISING SIGNIFICANCE OF BIOMARKER DISCOVERY & COMPANION DIAGNOSTICS
- 5.2. RISE OF POINT-OF-CARE (POC) TESTING
- 5.3. INCREASING DEMAND FOR CUSTOMIZED DIAGNOSTIC TESTS & PERSONALIZED MEDICINE
- 5.4. EXPANSION OF AI AND AUTOMATION IN DIAGNOSTICS
- 6. MARKET GROWTH ENABLERS
- 6.1. GROWING PREVALENCE OF CHRONIC & INFECTIOUS DISEASES
- 6.2. GROWING AWARENESS & EARLY DISEASE DETECTION
- 6.3. INNOVATIONS IN REAGENT FORMULATIONS
- 6.4. EXPANDING HEALTHCARE INFRASTRUCTURE & INVESTMENTS IN R&D
- 7. MARKET RESTRAINTS
- 7.1. HIGH COST OF ADVANCED DIAGNOSTIC TESTS
- 7.2. SUPPLY CHAIN DISRUPTIONS & RAW MATERIAL SHORTAGES
- 7.3. STRINGENT REGULATORY REQUIREMENTS
- 8. MARKET LANDSCAPE
- 8.1. MARKET OVERVIEW
- 8.2. MARKET SIZE & FORECAST
- 8.3. FIVE FORCES ANALYSIS
- 8.3.1. THREAT OF NEW ENTRANTS
- 8.3.2. BARGAINING POWER OF SUPPLIERS
- 8.3.3. BARGAINING POWER OF BUYERS
- 8.3.4. THREAT OF SUBSTITUTES
- 8.3.5. COMPETITIVE RIVALRY
- 9. REAGENT TYPE
- 9.1. MARKET SNAPSHOT & GROWTH ENGINE
- 9.2. MARKET OVERVIEW
- 9.3. IMMUNOCHEMICAL REAGENTS
- 9.3.1. MARKET OVERVIEW
- 9.3.2. MARKET SIZE & FORECAST
- 9.3.3. MARKET BY GEOGRAPHY
- 9.4. BIOCHEMICAL REAGENTS
- 9.4.1. MARKET OVERVIEW
- 9.4.2. MARKET SIZE & FORECAST
- 9.4.3. MARKET BY GEOGRAPHY
- 9.5. CHEMICAL REAGENTS
- 9.5.1. MARKET OVERVIEW
- 9.5.2. MARKET SIZE & FORECAST
- 9.5.3. MARKET BY GEOGRAPHY
- 10. TECHNOLOGY
- 10.1. MARKET SNAPSHOT & GROWTH ENGINE
- 10.2. MARKET OVERVIEW
- 10.3. IMMUNOASSAY & CLINICAL CHEMISTRY
- 10.3.1. MARKET OVERVIEW
- 10.3.2. MARKET SIZE & FORECAST
- 10.3.3. MARKET BY GEOGRAPHY
- 10.4. MOLECULAR DIAGNOSTICS
- 10.4.1. MARKET OVERVIEW
- 10.4.2. MARKET SIZE & FORECAST
- 10.4.3. MARKET BY GEOGRAPHY
- 10.5. HEMATOLOGY
- 10.5.1. MARKET OVERVIEW
- 10.5.2. MARKET SIZE & FORECAST
- 10.5.3. MARKET BY GEOGRAPHY
- 10.6. MICROBIOLOGY & CYTOLOGY
- 10.6.1. MARKET OVERVIEW
- 10.6.2. MARKET SIZE & FORECAST
- 10.6.3. MARKET BY GEOGRAPHY
- 10.7. OTHERS
- 10.7.1. MARKET OVERVIEW
- 10.7.2. MARKET SIZE & FORECAST
- 10.7.3. MARKET BY GEOGRAPHY
- 11. APPLICATION
- 11.1. MARKET SNAPSHOT & GROWTH ENGINE
- 11.2. MARKET OVERVIEW
- 11.3. INFECTIOUS DISEASES
- 11.3.1. MARKET OVERVIEW
- 11.3.2. MARKET SIZE & FORECAST
- 11.3.3. MARKET BY GEOGRAPHY
- 11.4. DIABETES
- 11.4.1. MARKET OVERVIEW
- 11.4.2. MARKET SIZE & FORECAST
- 11.4.3. MARKET BY GEOGRAPHY
- 11.5. CARDIOLOGY
- 11.5.1. MARKET OVERVIEW
- 11.5.2. MARKET SIZE & FORECAST
- 11.5.3. MARKET BY GEOGRAPHY
- 11.6. ONCOLOGY
- 11.6.1. MARKET OVERVIEW
- 11.6.2. MARKET SIZE & FORECAST
- 11.6.3. MARKET BY GEOGRAPHY
- 11.7. AUTOIMMUNE DISEASE
- 11.7.1. MARKET OVERVIEW
- 11.7.2. MARKET SIZE & FORECAST
- 11.7.3. MARKET BY GEOGRAPHY
- 11.8. OTHERS
- 11.8.1. MARKET OVERVIEW
- 11.8.2. MARKET SIZE & FORECAST
- 11.8.3. MARKET BY GEOGRAPHY
- 12. END-USERS
- 12.1. MARKET SNAPSHOT & GROWTH ENGINE
- 12.2. MARKET OVERVIEW
- 12.3. STANDARD REFERENCE LABS
- 12.3.1. MARKET OVERVIEW
- 12.3.2. MARKET SIZE & FORECAST
- 12.3.3. MARKET BY GEOGRAPHY
- 12.4. HOSPITAL-AFFILIATED LABS
- 12.4.1. MARKET OVERVIEW
- 12.4.2. MARKET SIZE & FORECAST
- 12.4.3. MARKET BY GEOGRAPHY
- 12.5. CLINICS
- 12.5.1. MARKET OVERVIEW
- 12.5.2. MARKET SIZE & FORECAST
- 12.5.3. MARKET BY GEOGRAPHY
- 12.6. OTHERS
- 12.6.1. MARKET OVERVIEW
- 12.6.2. MARKET SIZE & FORECAST
- 12.6.3. MARKET BY GEOGRAPHY
- 13. GEOGRAPHY
- 13.1. MARKET SNAPSHOT & GROWTH ENGINE
- 13.2. GEOGRAPHIC OVERVIEW
- 14. NORTH AMERICA
- 14.1. MARKET OVERVIEW
- 14.2. MARKET SIZE & FORECAST
- 14.2.1. REAGENT TYPE
- 14.2.2. TECHNOLOGY
- 14.2.3. APPLICATION
- 14.2.4. END-USER
- 14.3. KEY COUNTRIES
- 14.3.1. US: MARKET SIZE & FORECAST
- 14.3.2. CANADA: MARKET SIZE & FORECAST
- 15. EUROPE
- 15.1. MARKET OVERVIEW
- 15.2. MARKET SIZE & FORECAST
- 15.2.1. REAGENT TYPE
- 15.2.2. TECHNOLOGY
- 15.2.3. APPLICATION
- 15.2.4. END-USER
- 15.3. KEY COUNTRIES
- 15.3.1. GERMANY: MARKET SIZE & FORECAST
- 15.3.2. FRANCE: MARKET SIZE & FORECAST
- 15.3.3. RUSSIA: MARKET SIZE & FORECAST
- 15.3.4. SPAIN: MARKET SIZE & FORECAST
- 15.3.5. ITALY: MARKET SIZE & FORECAST
- 15.3.6. UK: MARKET SIZE & FORECAST
- 15.3.7. NETHERLANDS: MARKET SIZE & FORECAST
- 16. APAC
- 16.1. MARKET OVERVIEW
- 16.2. MARKET SIZE & FORECAST
- 16.2.1. REAGENT TYPE
- 16.2.2. TECHNOLOGY
- 16.2.3. APPLICATION
- 16.2.4. END-USER
- 16.3. KEY COUNTRIES
- 16.3.1. CHINA: MARKET SIZE & FORECAST
- 16.3.2. JAPAN: MARKET SIZE & FORECAST
- 16.3.3. INDIA: MARKET SIZE & FORECAST
- 16.3.4. SOUTH KOREA: MARKET SIZE & FORECAST
- 16.3.5. AUSTRALIA: MARKET SIZE & FORECAST
- 17. LATIN AMERICA
- 17.1. MARKET OVERVIEW
- 17.2. MARKET SIZE & FORECAST
- 17.2.1. REAGENT TYPE
- 17.2.2. TECHNOLOGY
- 17.2.3. APPLICATION
- 17.2.4. END-USER
- 17.3. KEY COUNTRIES
- 17.3.1. BRAZIL: MARKET SIZE & FORECAST
- 17.3.2. MEXICO: MARKET SIZE & FORECAST
- 17.3.3. ARGENTINA: MARKET SIZE & FORECAST
- 17.3.4. COLOMBIA: MARKET SIZE & FORECAST
- 18. MIDDLE EAST & AFRICA
- 18.1. MARKET OVERVIEW
- 18.2. MARKET SIZE & FORECAST
- 18.2.1. REAGENT TYPE
- 18.2.2. TECHNOLOGY
- 18.2.3. APPLICATION
- 18.2.4. END-USER
- 18.3. KEY COUNTRIES
- 18.3.1. TURKEY: MARKET SIZE & FORECAST
- 18.3.2. SAUDI ARABIA: MARKET SIZE & FORECAST
- 18.3.3. SOUTH AFRICA: MARKET SIZE & FORECAST
- 18.3.4. UAE: MARKET SIZE & FORECAST
- 19. COMPETITIVE LANDSCAPE
- 19.1. COMPETITION OVERVIEW
- 19.2. KEY VENDOR ANALYSIS
- 19.2.1. ABBOTT
- 19.2.2. DANAHER
- 19.2.3. F. HOFFMANN-LA ROCHE
- 19.2.4. SIEMENS HEALTHINEERS
- 19.2.5. THERMO FISHER SCIENTIFIC
- 20. KEY COMPANY PROFILES
- 20.1. ABBOTT
- 20.1.1. BUSINESS OVERVIEW
- 20.1.1. PRODUCT OFFERINGS
- 20.1.2. KEY STRATEGIES
- 20.1.3. KEY STRENGTHS
- 20.1.4. KEY OPPORTUNITIES
- 20.2. DANAHER
- 20.2.1. BUSINESS OVERVIEW
- 20.2.2. PRODUCT OFFERINGS
- 20.2.3. KEY STRATEGIES
- 20.2.4. KEY STRENGTHS
- 20.2.5. KEY OPPORTUNITIES
- 20.3. F. HOFFMANN-LA ROCHE
- 20.3.1. BUSINESS OVERVIEW
- 20.3.2. PRODUCT OFFERINGS
- 20.3.3. KEY STRATEGIES
- 20.3.4. KEY STRENGTHS
- 20.3.5. KEY OPPORTUNITIES
- 20.4. SIEMENS HEALTHINEERS
- 20.4.1. BUSINESS OVERVIEW
- 20.4.2. PRODUCT OFFERINGS
- 20.4.3. KEY STRATEGIES
- 20.4.4. KEY STRENGTHS
- 20.4.5. KEY OPPORTUNITIES
- 20.5. THERMO FISHER SCIENTIFIC
- 20.5.1. BUSINESS OVERVIEW
- 20.5.2. PRODUCT OFFERINGS
- 20.5.3. KEY STRATEGIES
- 20.5.4. KEY STRENGTHS
- 20.5.5. KEY OPPORTUNITIES
- 21. OTHER PROMINENT VENDORS
- 21.1. ATOMO DIAGNOSTICS
- 21.1.1. BUSINESS OVERVIEW
- 21.1.2. PRODUCT OFFERINGS
- 21.2. ACCELERATE DIAGNOSTICS
- 21.2.1. BUSINESS OVERVIEW
- 21.2.2. PRODUCT OFFERINGS
- 21.3. AGILENT TECHNOLOGIES
- 21.3.1. BUSINESS OVERVIEW
- 21.3.2. PRODUCT OFFERINGS
- 21.4. ALTONA DIAGNOSTICS
- 21.4.1. BUSINESS OVERVIEW
- 21.4.2. PRODUCT OFFERINGS
- 21.5. AMOY DIAGNOSTICS
- 21.5.1. BUSINESS OVERVIEW
- 21.5.2. PRODUCT OFFERINGS
- 21.6. ARKRAY
- 21.6.1. BUSINESS OVERVIEW
- 21.6.2. PRODUCT OFFERINGS
- 21.7. ACCUBIOTECH
- 21.7.1. BUSINESS OVERVIEW
- 21.7.2. PRODUCT OFFERINGS
- 21.8. BD
- 21.8.1. BUSINESS OVERVIEW
- 21.8.2. PRODUCT OFFERINGS
- 21.9. BIO-RAD LABORATORIES
- 21.9.1. BUSINESS OVERVIEW
- 21.9.2. PRODUCT OFFERINGS
- 21.10. BIOMÉRIEUX
- 21.10.1. BUSINESS OVERVIEW
- 21.10.2. PRODUCT OFFERINGS
- 21.11. BIOLYTICAL LABORATORIES
- 21.11.1. BUSINESS OVERVIEW
- 21.11.2. PRODUCT OFFERINGS
- 21.12. BIOCARTIS
- 21.12.1. BUSINESS OVERVIEW
- 21.12.2. PRODUCT OFFERINGS
- 21.13. BIOCEPT
- 21.13.1. BUSINESS OVERVIEW
- 21.13.2. PRODUCT OFFERINGS
- 21.14. BIOMERICA
- 21.14.1. BUSINESS OVERVIEW
- 21.14.2. PRODUCT OFFERINGS
- 21.15. BIOWAY BIOLOGICAL TECHNOLOGY
- 21.15.1. BUSINESS OVERVIEW
- 21.15.2. PRODUCT OFFERINGS
- 21.16. BOULE
- 21.16.1. BUSINESS OVERVIEW
- 21.16.2. PRODUCT OFFERINGS
- 21.17. CUPID
- 21.17.1. BUSINESS OVERVIEW
- 21.17.2. PRODUCT OFFERINGS
- 21.18. CHEMBIO DIAGNOSTICS
- 21.18.1. BUSINESS OVERVIEW
- 21.18.2. PRODUCT OFFERINGS
- 21.19. CPC DIAGNOSTICS
- 21.19.1. BUSINESS OVERVIEW
- 21.19.2. PRODUCT OFFERINGS
- 21.20. CPM SCIENTIFICA
- 21.20.1. BUSINESS OVERVIEW
- 21.20.2. PRODUCT OFFERINGS
- 21.21. DIALAB GMBH
- 21.21.1. BUSINESS OVERVIEW
- 21.21.2. PRODUCT OFFERINGS
- 21.22. DIASORIN S. P.A.
- 21.22.1. BUSINESS OVERVIEW
- 21.22.2. PRODUCT OFFERINGS
- 21.23. DIAGON
- 21.23.1. BUSINESS OVERVIEW
- 21.23.2. PRODUCT OFFERINGS
- 21.24. EDAN INSTRUMENTS
- 21.24.1. BUSINESS OVERVIEW
- 21.24.2. PRODUCT OFFERINGS
- 21.25. ILLUMINA
- 21.25.1. BUSINESS OVERVIEW
- 21.25.2. PRODUCT OFFERINGS
- 21.26. MERCK KGAA
- 21.26.1. BUSINESS OVERVIEW
- 21.26.2. PRODUCT OFFERINGS
- 21.27. MP BIOMEDICALS
- 21.27.1. BUSINESS OVERVIEW
- 21.27.2. PRODUCT OFFERINGS
- 21.28. ORASURE TECHNOLOGIES
- 21.28.1. BUSINESS OVERVIEW
- 21.28.2. PRODUCT OFFERINGS
- 21.29. QIAGEN
- 21.29.1. BUSINESS OVERVIEW
- 21.29.2. PRODUCT OFFERINGS
- 21.30. QUIDELORTHO
- 21.30.1. BUSINESS OVERVIEW
- 21.30.2. PRODUCT OFFERINGS
- 22. REPORT SUMMARY
- 22.1. KEY TAKEAWAYS
- 22.2. STRATEGIC RECOMMENDATIONS
- 23. QUANTITATIVE SUMMARY
- 23.1. MARKET BY GEOGRAPHY
- 23.1.1. IMMUNOCHEMICAL REAGENTS
- 23.1.2. BIOCHEMICAL REAGENTS
- 23.1.3. CHEMICAL REAGENTS
- 23.1.4. IMMUNOASSAY & CLINICAL CHEMISTRY
- 23.1.5. MOLECULAR DIAGNOSTICS
- 23.1.6. HEMATOLOGY
- 23.1.7. MICROBIOLOGY & CYTOLOGY
- 23.1.8. OTHER TECHNOLOGY
- 23.1.9. INFECTIOUS DISEASES
- 23.1.10. DIABETES
- 23.1.11. CARDIOLOGY
- 23.1.12. ONCOLOGY
- 23.1.13. AUTOIMMUNE DISEASES
- 23.1.14. OTHER APPLICATION
- 23.1.15. STANDARD REFERENCE LABS
- 23.1.16. HOSPITAL-AFFILIATED LABS
- 23.1.17. CLINICS
- 23.1.18. OTHER END-USER
- 24. APPENDIX
- 24.1. RESEARCH METHODOLOGY
- 24.2. RESEARCH PROCESS
- 24.3. REPORT ASSUMPTIONS & CAVEATS
- 24.3.1. KEY CAVEATS
- 24.3.2. CURRENCY CONVERSION
- 24.4. ABBREVIATIONS
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the global IVD reagents market?
What is the growth rate of the global IVD reagents market?
Which region dominates the global IVD reagents market share?
What are the significant trends in the IVD reagents market?
Who are the key players in the global IVD reagents market?
Other RELATED Reports
